Tigecycline vs. Clostridium perfringens
Yes — Clostridium perfringens is susceptible to tigecycline in vitro, and tigecycline is FDA‑labeled as active against C. perfringens for complicated intra‑abdominal infections. 1
- Drug label (highest‑priority, most recent): lists C. perfringens among pathogens for which tigecycline is indicated in complicated intra‑abdominal infections; therefore, it is considered susceptible for this labeled use and can be used clinically when source control is achieved. This directly supports morbidity/mortality/QOL benefit in its approved indication and population 1.
- Microbiology section: confirms in‑vitro activity against C. perfringens among anaerobes 1.
Nuances, pitfalls, and how to apply:
- Use tigecycline for intra‑abdominal infections involving C. perfringens, not for bacteremia or hospital/ventilator‑associated pneumonia, where mortality was higher and it is not indicated 1.
- Ensure source control; consider adding an agent with rapid clostridial toxin suppression (e.g., clindamycin) if severe toxin‑mediated soft‑tissue disease is suspected, as older SSTI guidance prioritizes toxin inhibition for gas gangrene; however, clindamycin resistance exists in a minority of C. perfringens strains, so verify susceptibility when used for toxin suppression 2.
- Dosing: use labeled dosing unless otherwise directed; avoid relying on tigecycline for bloodstream infection due to low serum levels, to prevent excess mortality and treatment failure impacting QOL and survival 1.